Home / Stocks / Dr. Agarwal's Eye Hosp L
DRAGARWQ

Dr. Agarwal's Eye Hosp L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 17 Nov 2026

₹5,834.0

Change

-161.5 (-2.69%)

Open

₹5,995.5

Prev. Close

₹5,995.5

Day High

₹5,997.0

Day Low

₹5,757.0

Volume Analysis

Traded

2,654

Delivered

1,903

Delivery %

71.7%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Promoter holding is rising
  • •Strong operating margin (31.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (22.7%)
  • •Strong 3-year revenue growth (20.7%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹6,208.34 ₹6,102.67 ₹5,968.34 ₹5,862.67 ₹5,728.34 ₹5,622.67 ₹5,488.34
Fibonacci ₹6,102.67 ₹6,010.99 ₹5,954.35 ₹5,862.67 ₹5,770.99 ₹5,714.35 ₹5,622.67
Camarilla ₹5,900.0 ₹5,878.0 ₹5,856.0 ₹5,862.67 ₹5,812.0 ₹5,790.0 ₹5,768.0

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-3.18%

1 Month

+16.44%

3 Months

+8.14%

6 Months

+12.74%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

20.03%

Net margin 14.86% × asset turnover 0.61x × equity multiplier 2.21x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Dr. Agarwal's Eye Hosp L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 78/100. The strongest factor is Growth (100/100), while Liquidity (52/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (31.0%). Strong 3-year EPS growth (22.7%).

TopFund Score — Fundamentals Quality

78/100 — Good

Data confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 17 Nov 2026 · How we calculate this →

Financial Strength

62

Growth

100

Cash Flow

86

Corporate Governance

75

Institutional Ownership

53

Business Quality

89

Risk & Volatility

90

Liquidity

52

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Record date set for Nov 18, 2026; shareholders get 23 AHCL shares for 2 AEHL shares.

NCLT-sanctioned amalgamation effective November 1, 2026; record date November 18, 2026 for share exchange.

Disclosure under Regulation 74(5) of the SEBI (DP) Regulations, 2018, is submitted.

NCLT sanctioned amalgamation of AEHL into AHCL; effective from April 1, 2026, pending conditions.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 (S) Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S)
Sales + 79 84 76 81 100 102 95 100 117 118 116 120 143
Expenses + 56 61 55 56 69 72 69 68 80 78 82 86 100
Operating Profit 23 23 21 24 31 30 26 32 37 40 34 34 43
OPM % 29.0% 28.0% 27.0% 30.0% 31.0% 29.0% 27.0% 32.0% 32.0% 34.0% 30.0% 28.0% 30.0%
Other Income + 0 1 1 2 0 2 2 0 1 1 3 2 2
Interest 2 2 2 2 3 4 4 3 4 4 2 2 3
Depreciation 6 6 7 8 10 9 10 10 11 11 12 12 11
Profit before tax 16 17 13 17 19 19 14 19 23 26 23 21 31
Tax % 26.0% 24.0% 26.0% 26.0% 25.0% 26.0% 26.0% 14.0% 26.0% 25.0% 26.0% 24.0% 24.0%
Net Profit + 12 13 9 13 14 14 10 16 17 19 17 16 23
EPS in Rs 25 27 20 27 30 30 22 34 37 40 36 34 48
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 18 22 20 16 27 22 25 24 17 15 22 20 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 118 137 149 153 170 176 140 201 268 319 397 471
Expenses + 103 119 126 129 140 129 109 143 192 227 277 324
Operating Profit 15 18 23 24 30 47 31 59 76 92 120 147
OPM % 13.0% 13.0% 15.0% 16.0% 18.0% 27.0% 22.0% 29.0% 28.0% 29.0% 30.0% 31.0%
Other Income + 0 -5 1 2 2 3 1 1 2 5 5 6
Interest 4 5 4 3 4 9 7 7 8 8 15 14
Depreciation 6 9 9 10 11 21 19 20 20 27 39 46
Profit before tax 5 0 11 13 17 20 6 32 49 62 71 94
Tax % -6.0% -104.0% 33.0% 49.0% 32.0% 31.0% 125.0% 25.0% 25.0% 26.0% 23.0% 25.0%
Net Profit + 6 0 7 7 12 14 -1 24 37 46 55 70
EPS in Rs 12 0 16 14 25 29 -3 51 79 99 116 145
Dividend Payout % 10.0% 940.0% 10.0% 8.0% 6.0% 0.0% 0.0% 6.0% 4.0% 3.0% 5.0% 5.0%
Sales growth 5 16 9 3 11 3 -21 44 33 19 24 19

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Reserves 19 19 25 30 41 51 50 73 109 152 205 341
Borrowings + 27 31 23 18 24 60 68 193 232 268 333 326
Other Liabilities + 18 24 20 28 31 24 33 42 44 71 71 94
Total Liabilities 69 79 72 81 100 141 155 314 390 496 613 766
Fixed Assets + 26 34 33 36 55 94 96 214 260 316 393 403
CWIP 0 1 1 3 0 0 0 26 62 97 128 197
Investments 0 0 0 0 0 0 0 0 0 0 13 89
Other Assets + 43 44 38 42 45 47 60 73 67 83 80 78
Total Assets 69 79 72 81 100 141 155 314 390 496 613 766
Equity Capital 5 5 5 5 5 5 5 5 5 5 5 5

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 14 17 20 19 25 39 34 57 70 90 94 145
Cash from Investing Activity + -10 -17 -8 -11 -25 -17 -11 -46 -71 -70 -133 -174
Cash from Financing Activity + -5 0 -12 -8 2 -20 -8 -4 0 -14 17 25
Net Cash Flow -1 0 0 0 2 2 15 7 -1 6 -23 -4
Free Cash Flow 3 1 12 7 0 22 23 10 -1 19 -9 47
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 106 113 103 98 111 96 120 112 107 112 95 105

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 71.89% → 72.67%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 27.47% 27.47% 27.46% 26.32% 26.22% 24.82% 24.29% 23.22% 23.15% 22.99% 23.03% 22.56%
Promoters 71.89% 71.89% 71.9% 71.9% 71.9% 71.9% 71.9% 72.67% 72.67% 72.67% 72.67% 72.67%
FII 0.63% 0.64% 0.65% 0.83% 0.84% 1.33% 1.49% 1.74% 1.82% 2.2% 2.24% 2.22%
DII 0.0% 0.0% 0.0% 0.96% 1.04% 1.95% 2.31% 2.36% 2.36% 2.12% 2.05% 2.54%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Dr. Agarwal's Eye Hosp L (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Dr. Agarwal's Eye Hosp L?

Frequently Asked Questions about Dr. Agarwal's Eye Hosp L

Community Sentiment

What are other investors saying about Dr. Agarwal's Eye Hosp L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.